WHITE BEAR LAKE, MINNESOTA – Envoy Medical Inc. (NASDAQ: COCH) has announced a significant stride in the development of its investigational Acclaim® cochlear implant, with all 56 patients enrolled in its pivotal clinical trial having successfully completed their three-month follow-up visits. This crucial benchmark brings the company closer to its goal of submitting a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), aiming to introduce a first-of-its-kind, fully implanted cochlear implant to the market.
The completion of these follow-up visits builds upon the company’s prior announcement that all 56 study participants had been successfully activated with the Acclaim device. These sequential milestones underscore Envoy Medical’s methodical progress through the rigorous stages of clinical evaluation. The company confirmed its continued dedication to collecting comprehensive safety data and other essential study measures, which are indispensable components for the forthcoming PMA application.
Advancing the Frontier of Hearing Technology
Brent Lucas, Chief Executive Officer of Envoy Medical, articulated the company’s determination, stating, "Envoy Medical continues to demonstrate its ability to execute. Each milestone achieved brings us one big step closer to our next major goal – submission of our PMA application to the FDA. We are steadily advancing toward our ultimate objective of bringing fully implanted cochlear implants to market in the United States." Lucas’s statement highlights the strategic importance of these clinical trial achievements in realizing the company’s long-term vision for innovative hearing solutions.
The Acclaim cochlear implant represents a potentially transformative advancement in the treatment of severe to profound sensorineural hearing loss. Unlike conventional cochlear implants that require external components worn behind the ear or on the head, the Acclaim is designed to be entirely internal. This fully implanted technology integrates a unique sensor that leverages the natural anatomy of the ear to capture sound, departing from the traditional microphone-based approach. This design aims to offer users a discreet, continuous, and potentially more natural hearing experience, free from the daily management and visibility issues associated with external devices.
Understanding the Clinical Trial and Regulatory Pathway
Pivotal clinical trials are the penultimate stage in the FDA approval process for medical devices, particularly those seeking Premarket Approval (PMA). A PMA is the most stringent type of device marketing application required by the FDA and is necessary for Class III devices, which are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. The Acclaim, given its implantable nature and critical function, falls into this category. The trial’s objective is to gather definitive evidence of the device’s safety and effectiveness in a controlled patient population, demonstrating that the benefits outweigh the risks.
The 56 patients enrolled in the Acclaim trial are individuals diagnosed with severe to profound sensorineural hearing loss, for whom hearing aids offer insufficient benefit. The successful completion of the three-month follow-up visits signifies that initial post-activation assessments, including device performance, patient adaptation, and any early safety concerns, have been reviewed. This data will be critical for the eventual PMA submission.
Looking ahead, Envoy Medical anticipates that all participants will complete their six-month visits by late 2026, with the comprehensive 12-month visit milestone for the full study projected to be reached by April 2027. This extended follow-up period is crucial for evaluating long-term performance, stability, and safety, providing a robust dataset for the FDA’s thorough review.
The Significance of Fully Implanted Technology
The concept of a fully implanted hearing device holds immense potential for individuals with hearing loss. Traditional cochlear implants, while highly effective, often present challenges related to comfort, aesthetics, and daily maintenance due to their external components. These components, including a sound processor, microphone, and transmitter coil, must be worn constantly, can interfere with activities like swimming, sleeping, or wearing certain headwear, and may carry a social stigma for some users.
A fully implanted system like the Acclaim aims to eliminate these concerns. By being entirely internal, it offers continuous 24/7 hearing without the need for daily attachment or removal. This could profoundly enhance the quality of life for recipients, fostering greater confidence, independence, and seamless integration into daily activities. The natural ear anatomy leveraging sensor is another key innovation, potentially offering a more authentic sound perception by utilizing the body’s inherent mechanisms for sound transmission. This could lead to improved sound localization, speech understanding in noise, and overall listening effort compared to external microphone systems.
FDA Breakthrough Device Designation: A Mark of Innovation
In 2019, the Acclaim Cochlear Implant received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration. This designation is granted to certain medical devices and device-led combination products that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The program is designed to help patients gain more timely access to these medical devices by expediting their development, assessment, and review.
Envoy Medical proudly notes that the Acclaim was believed to be the first hearing-focused device to receive this designation, and potentially remains the only hearing-focused medical technology to hold it. This status underscores the FDA’s recognition of the Acclaim’s potential to address a significant unmet medical need and its innovative approach to restoring hearing. The Breakthrough Device Designation facilitates closer collaboration with the FDA throughout the development and review process, potentially streamlining the path to market once clinical evidence supports approval.
The Broader Landscape of Hearing Loss and Treatment
Hearing loss is a global public health challenge, affecting hundreds of millions worldwide. According to the World Health Organization (WHO), over 1.5 billion people experience some degree of hearing loss, with 430 million having moderate or higher hearing loss in the better ear. In the United States, the National Institute on Deafness and Other Communication Disorders (NIDCD) reports that approximately 15% of American adults (37.5 million) aged 18 and over report some trouble hearing. For severe to profound sensorineural hearing loss, the most common type, traditional hearing aids often provide insufficient amplification and clarity, making cochlear implants the gold standard treatment.
While cochlear implants have revolutionized the lives of many, their adoption rates still fall short of the potential patient population. Barriers to adoption can include the cost, surgical risks, and, significantly, the aesthetic and practical considerations of external components. A fully implanted option could potentially remove some of these barriers, expanding access to effective treatment for a broader segment of the population struggling with profound hearing impairment. The global market for hearing devices is substantial and growing, driven by an aging population and increasing awareness of hearing health. The introduction of a fully implanted cochlear implant could represent a significant disruption and growth driver within this market segment.
Envoy Medical’s Commitment to Implantable Solutions
Envoy Medical Corporation is a hearing health company deeply committed to pioneering innovative technologies across the entire spectrum of hearing loss. Their focus is squarely on developing implantable hearing devices that significantly improve the quality of life for individuals grappling with hearing challenges. The company’s expertise in this specialized field is also evident in its other flagship product: the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI).
The Esteem FI-AMEI is currently the only FDA-approved, fully implanted active middle ear implant designed for adults with moderate to severe sensorineural hearing loss. This device offers 24/7 hearing capability by harnessing the ear’s natural anatomy. Crucially, the Esteem is invisible, requires no externally worn components, and nothing is placed within the ear canal for its operation. This eliminates the need for daily placement or removal, prevents loss, and negates regular cleaning, offering a seamless and continuous hearing experience. Its success in the market demonstrates Envoy Medical’s proven capability in developing and commercializing fully implanted hearing solutions. The experience gained from the Esteem’s development and regulatory approval undoubtedly informs and strengthens the company’s approach to the Acclaim cochlear implant.
Future Outlook and Potential Impact
The successful navigation of the Acclaim pivotal trial’s early phases, coupled with its Breakthrough Device Designation, positions Envoy Medical at the forefront of innovation in audiology. If approved, the fully implanted Acclaim cochlear implant could offer a paradigm shift for patients and clinicians alike. For patients, it promises not just restored hearing, but also enhanced discretion, convenience, and a potential reduction in the psychological burden often associated with visible hearing aids or traditional cochlear implant processors. For audiologists and ENT specialists, it would provide an additional, highly advanced option for patients who may be hesitant about external devices or seeking the utmost in discretion.
While the Acclaim remains an investigational device and is not yet approved for commercial use, the current progress is a strong indicator of its potential. The journey from clinical trial completion to FDA approval is arduous, requiring meticulous data analysis, comprehensive documentation, and a thorough review by regulatory bodies. However, the consistent achievement of milestones by Envoy Medical suggests a well-executed strategy and a strong commitment to bringing this innovative technology to those who need it most. The long-term impact could extend beyond individual patient benefits, potentially influencing future research and development in implantable medical devices across various specialties.
For additional information on the study and the Acclaim, interested parties can visit www.envoymedical.com/acclaim-pivotal.
About the Fully Implanted Acclaim® Cochlear Implant
The fully implanted Acclaim Cochlear Implant is poised to be a groundbreaking cochlear implant. Envoy Medical’s innovative technology incorporates a sensor designed to utilize the natural anatomy of the ear for sound capture, a distinct departure from conventional microphone systems. The Acclaim is specifically engineered to address severe to profound sensorineural hearing loss that is not adequately managed by traditional hearing aids. It is expected to be indicated for adults who have been thoroughly evaluated and deemed suitable candidates by a qualified physician. The device received the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation in 2019, signifying its potential to offer a more effective treatment for a debilitating condition.
CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. It is limited by United States law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the sole FDA-approved, fully implanted hearing device available for adults diagnosed with moderate to severe sensorineural hearing loss. It facilitates continuous 24/7 hearing by leveraging the ear’s natural physiological mechanisms. The Esteem FI-AMEI hearing implant is completely invisible, requires no external components, and nothing is positioned within the ear canal for its function. This eliminates the need for daily application or removal, safeguards against loss, and removes the requirement for routine cleaning, thereby offering genuine 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for both the Esteem and the investigational Acclaim can be found at: https://www.envoymedical.com/safety-information.
About Envoy Medical Corporation
Envoy Medical Corporation is a dedicated hearing health company focused on delivering innovative technologies across the entire spectrum of hearing loss. The company is committed to enhancing the quality of life for individuals with hearing loss through the pioneering development of advanced implantable hearing devices.
